Syenex
Syenex develops synthetic biology delivery tools — including the VivoCell Platform and UltraCell Technology — for cell and gene therapy drug developers, targeting enterprise biotech, CDMO, and clinical-stage therapeutic companies with licensing and CDMO integration partnerships.
- Company typePrivate
- Founded2022
- HeadquartersEvanston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Syenex does
Syenex is a privately held synthetic biology platform company founded in 2022 and headquartered in Evanston, Illinois, that develops next-generation delivery tools for cell and gene therapy drug developers. The company builds enveloped viral vector technologies — including the VivoCell Platform for in vivo T-cell engineering (eliminating ex vivo manipulation in CAR-T manufacturing), UltraCell Technology for improved lentiviral vector productivity, Cell Specific Delivery surface compositions optimized for T-cell targeting, and Programmable Payloads compatible with retroviral integrase-based systems — that address supply chain, quality, and cost bottlenecks in genetic medicine manufacturing.
The company monetizes through licensing, platform access fees, and CDMO integration partnerships, targeting enterprise biotech and pharmaceutical customers developing cell and gene therapies. Its go-to-market combines direct enterprise engagement via website-based intake forms with channel partnerships through CDMO integrations (Bionova Scientific, uBriGene Biosciences) and strategic co-development agreements with clinical-stage therapeutic developers (Leucid Bio) and clinical infrastructure JVs (CTMC, an MD Anderson/Resilience joint venture). Pricing is quote-based and not publicly disclosed, consistent with bespoke enterprise licensing arrangements at early commercialization stage.
Syenex operates with a small multidisciplinary team of approximately 6 named contributors (Co-Founder & CEO Jay Rosanelli, Co-Founder & CSO Josh Leonard, VP R&D Matteo Stoppato, Director of Operations Teresa Nikolich, and Senior Scientists), with AlleyCorp as a disclosed institutional backer. The company pursues an ecosystem strategy anchored on embedded technology integrations across multiple CDMO platforms, with partnerships concentrated in late 2025 and early 2026 indicating active commercial expansion into the cell and gene therapy value chain.
Syenex firmographics
Firmographics- Name
- Syenex
- Legal name
- Syenex
- Website
- https://syenex.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Syenex develops synthetic biology delivery tools — including the VivoCell Platform and UltraCell Technology — for cell and gene therapy drug developers, targeting enterprise biotech, CDMO, and clinical-stage therapeutic companies with licensing and CDMO integration partnerships.
- Ownership category
- akta.pro rank
Syenex industry classification
Industry- Product category
- Cell and Gene Therapy Delivery Technologies
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
- akta.pro secondary industry
- Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)
Keywords
Where Syenex is headquartered
LocationHeadquarters
- HQ city
- Evanston
- HQ country
- United States
- HQ region
- North America
Markets served
Syenex business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Technology Licensing & Platform Access: Syenex provides its delivery technologies and bioengineering systems to drug developers through licensing arrangements and platform access partnerships. Revenue derived from CDMO integrations, technology access fees, and regulatory support services.
- Manufacturing Alliance Revenue: Partnership with Bionova Scientific positions Syenex's delivery technologies as preferred manufacturing solutions, generating revenue through preferred partner status and integration of technologies into manufacturing workflows.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Syenex product offering
Product offeringCore offering
Syenex develops and licenses synthetic biology delivery tools and bioengineering platforms for cell and gene therapy developers. Its core VivoCell Platform enables in vivo T-cell engineering that eliminates ex vivo manipulation, while the UltraCell Technology improves lentiviral vector productivity, yield, and cost in GMP manufacturing. The technology is delivered to drug developers through licensing arrangements, CDMO manufacturing integrations, and co-development partnerships.
Product overview
Syenex is a genetic medicines platform company offering a unified portfolio of delivery technologies for cell and gene therapies. The core offering is the VivoCell Platform, which enables in vivo T-cell engineering. This platform is enhanced by the UltraCell Technology for improved lentiviral vector manufacturing. Supporting technologies include Cell Specific Delivery (optimized for T-cell targeting) and Programmable Payloads (compatible with various cell engineering payloads). The company focuses on bioengineering tools that improve delivery efficiency, scalability, and regulatory pathway support for drug developers.
Differentiator
Problem solved
Functional benefit
Brands
- VivoCell Platform: A next-generation in vivo delivery platform for CAR-T cell engineering and T-cell targeting, enabling cell type specific delivery of genetic medicines.
Products and services
- VivoCell Platform A next-generation in vivo delivery platform that enables direct engineering of T-cells within the body, eliminating the need for ex vivo manipulation in CAR-T therapy manufacturing. Targeted at drug developers and therapeutic companies developing cell and gene therapies.
- UltraCell Technology Syenex's proprietary next-generation delivery technology integrated into partner CDMO manufacturing platforms to improve lentiviral vector productivity, yield, and manufacturability while reducing costs. Targeted at CDMOs and therapeutic developers requiring scalable lentiviral vector manufacturing.
Quantifiable outcome
- Reduced comparability risk and improved lentiviral vector manufacturability in GMP manufacturing
- +2 more outcomes
Companies that use Syenex
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles2 records
Syenex technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Syenex partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Bionova ScientificcoreStrategic manufacturing alliance combining Bionova's proprietary IS-free plasmid DNA manufacturing platform with Syenex's delivery technologies. Addresses critical bottlenecks in pricing, quality, and supply-chain reliability for pDNA. Enables therapeutic developers to progress from early-stage RUO plasmids through GMP manufacturing with reduced comparability risk.
- uBriGene BiosciencescoreStrategic partnership integrating Syenex's UltraCell technology into uBriGene's LVV Turbo GMP lentiviral vector manufacturing platform. The integration aims to improve productivity, yield, and reduce costs in lentiviral manufacturing for cell therapy development.
- Leucid BiocoreStrategic collaboration to develop in vivo CAR-T cell therapies leveraging Syenex's VivoCell Platform for delivery of Leucid's LEU011 asset. Partnership aims to accelerate clinical development and manufacturing for solid tumor treatment, with potential to shift toward more scalable, off-the-shelf therapy. Supports Leucid's ongoing Phase I/IIa AERIAL trial.
- CTMCcorePartnership between CTMC (joint venture between MD Anderson Cancer Center and Resilience) and Syenex to improve scalability and efficiency of engineered T cell therapies. CTMC utilizes Syenex's bioengineering systems which significantly enhance gene delivery efficiency and manufacturing timelines.
Scale indicators1 record
Recent moves6 records
Expansion highlights4 records
Syenex competitors and assessment
Company assessmentDirect peers
- Dyno Therapeutics: Dyno applies AI-driven capsid engineering to develop improved AAV vectors for gene therapy delivery, with partnerships across multiple pharma companies. Comparable to Syenex as an engineered-delivery-platform company targeting cell-type-specific delivery for genetic medicines.
- Strand Therapeutics: Strand develops synthetic biology-based mRNA circuits for cell therapy and oncology, including controllable gene expression systems. Comparable to Syenex as a programmable, synthetic-biology-enabled delivery and gene expression platform for cell and gene therapies.
- Acuitas Therapeutics: Acuitas develops lipid nanoparticle (LNP) delivery technology used in approved mRNA therapeutics. Like Syenex, it operates as a delivery technology platform partner rather than a drug developer, licensing its technology to pharma and biotech customers.
- MaxCyte: MaxCyte provides electroporation-based delivery technology for cell engineering, with a Flow Electroporation platform used by clinical-stage cell therapy developers. Directly comparable to Syenex as a non-viral delivery technology enabler for cell therapy manufacturing.
Emerging players
- Cellectis: Cellectis develops gene-edited allogeneic CAR-T cell therapies and provides cell engineering platforms to partners. Comparable to Syenex as a gene/cell engineering technology company with both internal programs and external platform partnerships.
- Intellia Therapeutics: Intellia is a clinical-stage developer of in vivo CRISPR/Cas9 gene editing therapies delivered via lipid nanoparticles. Comparable to Syenex as a company advancing in vivo delivery and editing as alternatives to ex vivo cell manipulation.
- Verve Therapeutics: Verve is developing in vivo gene editing therapies for cardiovascular disease using lipid nanoparticle delivery. Comparable to Syenex's in vivo delivery thesis (VivoCell) as a clinical-stage developer demonstrating in vivo cell engineering as an alternative to ex vivo approaches.
Broad incumbents
- Editas Medicine: Editas is a clinical-stage CRISPR gene editing company developing in vivo and ex vivo gene-edited medicines. Comparable to Syenex's broader cell and gene therapy delivery and editing category, though Editas operates as a drug developer with internal programs.
- CRISPR Therapeutics: CRISPR Therapeutics is a leading clinical-stage gene editing company with approved Casgevy therapy and broad ex vivo / in vivo programs. Comparable to Syenex as a broader cell and gene therapy platform, though CRISPR Therapeutics is much larger and operates as a drug developer.
- Telesis Bio: Telesis Bio (formerly Codex DNA) provides synthetic biology tools and automated platforms for DNA synthesis and protein engineering. Comparable to Syenex as a synthetic biology tools company enabling downstream therapeutic development, though operating upstream of the delivery focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Syenex social profiles
Digital presenceSyenex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Syenex leadership team
Management profileNumber of profiles
Profiles6 records
Syenex funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Syenex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Syenex
What does Syenex do?
Syenex develops and licenses synthetic biology delivery tools and bioengineering platforms for cell and gene therapy developers. Its core VivoCell Platform enables in vivo T-cell engineering that eliminates ex vivo manipulation, while the UltraCell Technology improves lentiviral vector productivity, yield, and cost in GMP manufacturing. The technology is delivered to drug developers through licensing arrangements, CDMO manufacturing integrations, and co-development partnerships.
Is Syenex a public or private company?
Syenex is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Syenex founded?
Syenex was founded in 2022. It employs 11 to 50 people.
Where is Syenex based?
Syenex is headquartered in Evanston, United States, in the North America region.
How does Syenex make money?
Two revenue lines are on record. Technology Licensing & Platform Access are the primary driver. The others are manufacturing Alliance Revenue.
Who are Syenex's main competitors?
Direct peers on record are Dyno Therapeutics, Strand Therapeutics, Acuitas Therapeutics and MaxCyte. Emerging players are Cellectis, Intellia Therapeutics and Verve Therapeutics. Broad incumbents are Editas Medicine, CRISPR Therapeutics and Telesis Bio.
Does Syenex have an API?
No public API is recorded for Syenex.
What industry is Syenex in?
Syenex's product category is Cell and Gene Therapy Delivery Technologies. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services. Its NAICS code is 541714 and its SIC code is 2834.